LV12720B - Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof - Google Patents

Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof Download PDF

Info

Publication number
LV12720B
LV12720B LVP-01-26A LV010026A LV12720B LV 12720 B LV12720 B LV 12720B LV 010026 A LV010026 A LV 010026A LV 12720 B LV12720 B LV 12720B
Authority
LV
Latvia
Prior art keywords
amino
oxybutylidene
sodium
compound according
bisphosphonic acid
Prior art date
Application number
LVP-01-26A
Other languages
English (en)
Latvian (lv)
Other versions
LV12720A (lv
Inventor
Nina Finkelstein
Ramy Lidor-Hadas
Judith Aronhime
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of LV12720A publication Critical patent/LV12720A/xx
Publication of LV12720B publication Critical patent/LV12720B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LVP-01-26A 1998-08-27 2001-04-05 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof LV12720B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US12974399P 1999-04-16 1999-04-16
US14446199P 1999-07-19 1999-07-19
PCT/US1999/019838 WO2000012517A1 (en) 1998-08-27 1999-08-27 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
LV12720A LV12720A (lv) 2001-09-20
LV12720B true LV12720B (en) 2002-02-20

Family

ID=27378576

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-01-26A LV12720B (en) 1998-08-27 2001-04-05 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Country Status (30)

Country Link
US (2) US6281381B1 (enExample)
EP (1) EP1107974B1 (enExample)
JP (2) JP2002523514A (enExample)
KR (2) KR20070034132A (enExample)
AT (1) ATE334993T1 (enExample)
AU (1) AU5698899A (enExample)
BG (1) BG65329B1 (enExample)
BR (1) BR9913472A (enExample)
CA (1) CA2341459A1 (enExample)
CZ (1) CZ2001629A3 (enExample)
DE (1) DE69932620T2 (enExample)
DK (1) DK1107974T3 (enExample)
EA (1) EA002739B1 (enExample)
EE (1) EE04552B1 (enExample)
ES (1) ES2270613T3 (enExample)
HR (1) HRP20010129A2 (enExample)
HU (1) HUP0203078A3 (enExample)
IL (1) IL141423A (enExample)
IS (1) IS5864A (enExample)
LT (1) LT4888B (enExample)
LV (1) LV12720B (enExample)
NO (1) NO20010957L (enExample)
NZ (1) NZ510682A (enExample)
PL (1) PL346347A1 (enExample)
PT (1) PT1107974E (enExample)
RO (1) RO122854B1 (enExample)
SI (1) SI20581B (enExample)
SK (1) SK2482001A3 (enExample)
WO (1) WO2000012517A1 (enExample)
YU (1) YU14701A (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406910B1 (fr) * 2001-07-16 2010-01-13 Universite Paris 13 Procedes de preparation de derives de bisphosphonates
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
HUP0600680A3 (en) * 2001-12-24 2008-04-28 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
JP2005531532A (ja) * 2002-04-05 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
WO2005035542A1 (en) * 2003-10-14 2005-04-21 Pliva-Istrazivanje I Razvoj D.O.O. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
DK1753395T3 (da) 2004-05-24 2010-11-08 Warner Chilcott Co Llc Enterisk, fast, oral doseringsform af et bisphosphonat, der indeholder et chelateringsmiddel
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
ES2331015T3 (es) * 2004-10-29 2009-12-18 Sandoz Ag Proceso para la preparacion de un glatiramero.
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
NZ589053A (en) * 2006-10-27 2012-03-30 Signal Pharm Llc Process of preparing 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
JP5244608B2 (ja) * 2006-11-22 2013-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 二糖類化合物のナトリウム塩及びその製造方法並びにその使用
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
US8629178B2 (en) * 2009-11-03 2014-01-14 Li Liu Sodium tanshinone IIA sulfonate hydrate and preparation method and use thereof
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5039819A (en) 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
US5159108A (en) 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
CA2221844A1 (en) 1995-06-06 1996-12-12 Merck & Co., Inc. Disodium alendronate formulations
DK0833643T3 (da) * 1995-06-06 2005-05-30 Merck & Co Inc Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme

Also Published As

Publication number Publication date
HUP0203078A2 (hu) 2003-01-28
US20030065214A1 (en) 2003-04-03
BR9913472A (pt) 2002-03-05
EP1107974A1 (en) 2001-06-20
DK1107974T3 (da) 2006-10-30
EE04552B1 (et) 2005-10-17
US6281381B1 (en) 2001-08-28
EA002739B1 (ru) 2002-08-29
NO20010957L (no) 2001-04-26
JP2009143955A (ja) 2009-07-02
SI20581B (sl) 2008-06-30
AU5698899A (en) 2000-03-21
IL141423A (en) 2005-09-25
DE69932620T2 (de) 2006-12-14
HUP0203078A3 (en) 2005-01-28
SK2482001A3 (en) 2002-01-07
EA200100184A1 (ru) 2001-10-22
RO122854B1 (ro) 2010-03-30
EE200100126A (et) 2002-06-17
LT2001016A (en) 2001-10-25
KR20010079701A (ko) 2001-08-22
EP1107974A4 (en) 2001-09-26
LV12720A (lv) 2001-09-20
WO2000012517A9 (en) 2000-07-13
US6696601B2 (en) 2004-02-24
HRP20010129A2 (en) 2005-04-30
JP2002523514A (ja) 2002-07-30
IS5864A (is) 2001-02-26
DE69932620D1 (de) 2006-09-14
PT1107974E (pt) 2006-10-31
CA2341459A1 (en) 2000-03-09
YU14701A (sh) 2003-01-31
WO2000012517A1 (en) 2000-03-09
EP1107974B1 (en) 2006-08-02
ATE334993T1 (de) 2006-08-15
SI20581A (sl) 2001-12-31
IL141423A0 (en) 2002-03-10
PL346347A1 (en) 2002-02-11
KR20070034132A (ko) 2007-03-27
NO20010957D0 (no) 2001-02-26
NZ510682A (en) 2003-09-26
CZ2001629A3 (cs) 2001-08-15
LT4888B (lt) 2002-02-25
BG65329B1 (bg) 2008-02-29
BG105292A (en) 2001-12-29
ES2270613T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
LV12720B (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US7687636B2 (en) Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
MXPA04010009A (es) Polimorfos y pseudopolimorfos de sodio de risedronato novedosos.
EP1924587B1 (en) A crystalline form of the zoledronic acid, a process to obtain it and the pharmaceutical composition comprising it
US6963008B2 (en) Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
EP1702924A2 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US20250197429A1 (en) Tin containing organometallic compounds
AU2004202301B2 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
SK50782006A3 (sk) Amorfné formy risedronátu monosodného
MXPA01002017A (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
CN111909048B (zh) 一种多组分一锅法合成阿托伐他汀钙中间体的方法
EP1928889A1 (en) Pharmaceutically acceptable salts and hydrates of risedronic acid
EP1923052A1 (en) Novel polymorphs and pseudopolymorphs of risedronate sodium
WO1997031004A1 (en) A process for the preparation of diphosphonate derivatives
JPWO1987007609A1 (ja) １，１，２‐トリアリール‐１‐ブテン誘導体